A clinical study of percutaneous injection of the artificial bone in the treatment of benign bone tumors

YANG Yong-kun; NIU Xiao-hui; LI Yuan; LIU Wei-feng; XU Hai-rong

doi:10.3969/j.issn.2095-252X.2019.01.007

Abstract：Objective To evaluate whether artificial bone replacement material can rapidly reconstruct the bone strength through minimally invasive surgery and achieve safe healing effects.Methods From August 2016 to February 2017, 10 cases of benign bone tumor were treated by percutaneous injection of the artificial bone substitute in our department.All were diagnosed as bone cysts.All the tumors located in the long tubular bones (4 femur, 5 humerus, 1 tibia).The bone resorption and transformation process, outcomes of the bone grafting were evaluated by postoperative follow-up.Postoperative MSTS score and complications were recorded.Results The average followup was 12.4 months (range:8-17 months).The average transformation rate was 98.8％ (range:90％-100％) at the end of follow-up.All cases healed well.Eight cases had been followed up for 1 year and the transformation rate was100％.There were no significant correlations between the transformation rate and age (P=0.552), location (P=0.781), bone graft volume (P=0.508) after bone grafting.The average MSTS score was 29.3.In 5 patients, a small amount of artificial bone spilled out of the bone cortex through the puncture path, which was completely absorbed4-5 months postoperatively.There was no osteogenesis in soft tissues.No recurrence, fracture, wound infection or other complications was noted.Conclusions The injection type calcium sulfate/calcium phosphate compound bone graft can be used to treat benign bone tumors represented by bone cyst.The clinical effects are satisfactory and the healing rate is high.The bone strength can be maintained after bone grafting.The postoperative functional recovery is good and the complication rate is low.